RT Journal Article
SR Electronic
T1 Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries
JF BMJ Open
JO BMJ Open
FD British Medical Journal Publishing Group
SP e047258
DO 10.1136/bmjopen-2020-047258
VO 11
IS 7
A1 Sing, Chor-Wing
A1 Lin, Tzu-Chieh
A1 Bartholomew, Sharon
A1 Bell, J Simon
A1 Bennett, Corina
A1 Beyene, Kebede
A1 Bosco‐Lévy, Pauline
A1 Chan, Amy Hai Yan
A1 Chandran, Manju
A1 Cheung, Ching-Lung
A1 Doyon, Caroline Y
A1 Droz-Perroteau, Cécile
A1 Ganesan, Ganga
A1 Hartikainen, Sirpa
A1 Ilomaki, Jenni
A1 Jeong, Han Eol
A1 Kiel, Douglas P
A1 Kubota, Kiyoshi
A1 Lai, Edward Chia-Cheng
A1 Lange, Jeff
A1 Lewiecki, E Michael
A1 Liu, Jiannong
A1 Man, Kenneth K C
A1 Mendes de Abreu, Mirhelen
A1 Moore, Nicolas
A1 O’Kelly, James
A1 Ooba, Nobuhiro
A1 Pedersen, Alma B
A1 Prieto-Alhambra, Daniel
A1 Shin, Ju-Young
A1 Sørensen, Henrik T
A1 Tan, Kelvin Bryan
A1 Tolppanen, Anna-Maija
A1 Verhamme, Katia M C
A1 Wang, Grace Hsin-Min
A1 Watcharathanakij, Sawaeng
A1 Zhao, Hongxin
A1 Wong, Ian C K
YR 2021
UL http://bmjopen.bmj.com/content/11/7/e047258.abstract
AB Introduction Hip fractures are associated with a high burden of morbidity and mortality. Globally, there is wide variation in the incidence of hip fracture in people aged 50 years and older. Longitudinal and cross-geographical comparisons of health data can provide insights on aetiology, risk factors, and healthcare practices. However, systematic reviews of studies that use different methods and study periods do not permit direct comparison across geographical regions. Thus, the objective of this study is to investigate global secular trends in hip fracture incidence, mortality and use of postfracture pharmacological treatment across Asia, Oceania, North and South America, and Western and Northern Europe using a unified methodology applied to health records.Methods and analysis This retrospective cohort study will use a common protocol and an analytical common data model approach to examine incidence of hip fracture across population-based databases in different geographical regions and healthcare settings. The study period will be from 2005 to 2018 subject to data availability in study sites. Patients aged 50 years and older and hospitalised due to hip fracture during the study period will be included. The primary outcome will be expressed as the annual incidence of hip fracture. Secondary outcomes will be the pharmacological treatment rate and mortality within 12 months following initial hip fracture by year. For the primary outcome, crude and standardised incidence of hip fracture will be reported. Linear regression will be used to test for time trends in the annual incidence. For secondary outcomes, the crude mortality and standardised mortality incidence will be reported.Ethics and dissemination Each participating site will follow the relevant local ethics and regulatory frameworks for study approval. The results of the study will be submitted for peer-reviewed scientific publications and presented at scientific conferences.